

Biovica presents at the Annual Biomarkers Congress in Manchester, 2019

Uppsala, Sweden, January 21, 2019. Mattias Bergqvist, Biovica, is invited to give an oral presentation at the 14th Annual Biomarkers Congress 21-22 February 2019, Manchester, UK.

At the conference Mattias will address how liquid biomarkers can constitute novel ways to more effectively evaluate oncology drugs in development. Enhanced evaluation of drug efficacy by new assays such as DiviTum[®] can save time & cost and provide key information during preclinical and clinical trials, with the aim to bring new drugs to the market faster with a higher probability of regulatory success. DiviTum[®] measures cell proliferation and offers a new solution for measuring effects of drugs that inhibit the cell cycle – like the new CDK4/6 inhibitors and many other new promising compounds.

The Biomarker Congress includes presentations, case studies, novel technologies and panel discussions focused on the opportunities and challenges of biomarker development.

“This is a great opportunity to interact with Biovica’s target audience and present the possibilities of DiviTum[®] to key people in the industry. I look forward to present the unique study results of DiviTum[®] as a liquid biomarker for fast evaluation of drugs that inhibit the cell cycle. It’s great to be invited again to present at the congress on the highly interesting and actual topic of liquid biomarkers in oncology drug development and clinical validation”, says Mattias Bergqvist, Clinical Development Director at Biovica.

Link for more information on the congress:

<https://www.oxfordglobal.co.uk/biomarkers-congress/>

Biovica International is a company focused on providing liquid biomarkers for measuring cell proliferation and efficacy evaluation of cancer drugs. Mattias Bergqvist has global responsibility for clinical strategy and developing the clinical study program in collaboration with Biovica’s partners in the US & EU. During his more than 20 years of experience in the pharmaceutical and biotechnology industry, he has been Therapeutic Area Director, Oncology at AstraZeneca Nordics and worked in the Global Oncology Department, AstraZeneca UK. His areas of expertise include clinical study and market strategy during drug and biomarker development.

Contact

Anders Rylander, CEO Biovica.

Phone: +46 (0)18 444 48 35,

E-mail: anders.rylander@biovica.com

In the event of contradictions or differences between the Swedish press release and this English translation of the Swedish press release, the Swedish text shall be given priority.

Biovica – Best Possible Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum[®] assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum[®] is CE labelled and MPA registered. Appointed Certified Adviser is FNCA Sweden AB, info@fnca.se, +46 8 528 00 399.

Webb www.biovica.com

Contact info@biovica.com